Parkinsonism & Related Disorders
Volume 16, Issue 7 , Pages 471-474 , August 2010

A case control study on bone mineral density in Chinese patients with Parkinson’s disease

  • Kuen Lam

      Affiliations

    • Department of Medicine, Shatin Cheshire Home, 30 A Kung Kok Sang Road, Shatin, Hong Kong
    • Corresponding Author InformationCorresponding author. Tel.: +852 90975625.
    • ,
  • Martin Li

      Affiliations

    • Department of Medicine and Therapeutic, Prince of Wales Hospital, Hong Kong
    • ,
  • Vincent Mok

      Affiliations

    • Department of Medicine and Therapeutic, Prince of Wales Hospital, Hong Kong
    • ,
  • Andrew Hui

      Affiliations

    • Department of Medicine and Therapeutic, Prince of Wales Hospital, Hong Kong
    • ,
  • Jean Woo

      Affiliations

    • Department of Medicine and Therapeutic, Prince of Wales Hospital, Hong Kong

Received 5 November 2009 ,Revised 12 March 2010 ,Accepted 7 May 2010.

References 

  1. Invernizzi M, Carda S, Viscontini GS, Cisari C. Osteoporosis in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(5):339–346
  2. Taggart H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing. 1995;24(4):326–328
  3. Yamada T, Kachi T, Ando K. Osteoporosis and fractures in Parkinson’s disease. Nippon Ronen Igakkai Zasshi. 1995;32(10):637–640
  4. Song IU, Kim JS, Lee SB, Ryu SY, An JY, Jeong DS, et al. The relationship between low bone mineral density and Parkinson’s disease in a Korean population. J Clin Neurosci. 2009;16(6):807–809
  5. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun. 1994;15(3):173–177
  6. Wood B, Walker R. Osteoporosis in Parkinson’s disease. Mov Disord. 2005;20(12):1636–1640
  7. Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. Bone mineral density in hip-fracture patients with Parkinson’s disease: a case-control study. Arch Phys Med Rehabil. 2006;87(11):1459–1462
  8. Bezza A, Ouzzif Z, Naji H, Achemlal L, Mounach A, Nouijai M, et al. Prevalence and risk factors of osteoporosis in patients with Parkinson’s disease. Rheumatol Int. 2008;28(12):1205–1209
  9. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology. 1997;49(5):1273–1278
  10. Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing. 2009;38(6):675–680
  11. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW, Lentle BC. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8(4):371–378
  12. Woo J, Li M, Lau E. Population bone mineral density measurements for Chinese women and men in Hong Kong. Osteoporos Int. 2001;12(4):289–295
  13. Lau E, Donnan S, Barker DJ, Cooper C. Physical activity and calcium intake in fracture of the proximal femur in Hong Kong. BMJ. 1988;297(6661):1441–1443
  14. Celentano E, Galasso R, Berrino F, Fusconi E, Giurdanella MC, Tumino R, et al. Correlates of age at natural menopause in the cohorts of EPIC-Italy. Tumori. 2003;89(6):608–614
  15. Mishra G, Hardy R, Kuh D. Are the effects of risk factors for timing of menopause modified by age? Results from a British birth cohort study. Menopause. 2007;14(4):717–724
  16. Lawlor DA, Ebrahim S, Smith GD. The association of socio-economic position across the life course and age at menopause: the British Women’s Heart and Health Study. BJOG. 2003;110(12):1078–1087
  17. Ragonese P, D’Amelio M, Savettieri G. Implications for estrogens in Parkinson’s disease: an epidemiological approach. Ann N Y Acad Sci. 2006;1089:373–382
  18. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000;54(12):2292–2298
  19. Tripanichkul W, Sripanichkulchai K, Duce JA, Finkelstein DI. 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult. Brain Res. 2007;1164:24–31
  20. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson’s disease. Clin Exp Pharmacol Physiol. 2007;34(7):555–565
  21. Ragonese P, D’Amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004;62(11):2010–2014
  22. Sakajiri K, Takamori M. Body fat loss in patients with Parkinson’s disease. Rinsho Shinkeigaku. 1997;37(7):611–614
  23. Markus HS, Tomkins AM, Stern GM. Increased prevalence of undernutrition in Parkinson’s disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect. 1993;5(2):117–125
  24. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC. Weight change and body composition in patients with Parkinson’s disease. J Am Diet Assoc. 1995;95(9):979–983
  25. Cushing ML, Traviss KA, Calne SM. Parkinson’s disease: implications for nutritional care. Can J Diet Pract Res. 2002;63(2):81–87
  26. Reid IR. Relationships among body mass, its components, and bone. Bone. 2002;31(5):547–555
  27. Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. Skeletal muscle mass, fat mass, and hip bone mineral density in elderly women with hip fracture. J Bone Miner Metab. 2007;25(4):237–242
  28. Wat WZ, Leung JY, Tam S, Kung AW. Prevalence and impact of vitamin D insufficiency in southern Chinese adults. Ann Nutr Metab. 2007;51(1):59–64
  29. Newmark HL, Newmark J. Vitamin D and Parkinson’s disease – a hypothesis. Mov Disord. 2007;22(4):461–468

☆ The review of this paper was entirely handled by an Associate Editor, Eng-King Tan.

PII: S1353-8020(10)00109-4

doi: 10.1016/j.parkreldis.2010.05.002

Parkinsonism & Related Disorders
Volume 16, Issue 7 , Pages 471-474 , August 2010

Article Tools